Carter Gould

Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings

Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential

Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

Pfizer Analysts See 'Surprisingly Strong' Vaccine Updates In Q2, Question Biopharma's Blockbuster Potential

Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

UBS Upgrades Gilead, Sees EPS Upside In 2019

Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'

UBS Upgrades Gilead, Sees EPS Upside In 2019

Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'

UBS: Buy Biogen For Pipeline, M&A Potential

UBS Loses Conviction In Spark Therapeutics, Downgrades

Carter Gould Recent News

Pipeline Bomb: Analysts Review Celgene's Crohn's Diseases Failure

UBS Cuts Price Target On Celgene To $146 As GED Drops Out

'Poor Quality' Amgen Earnings Beat Doesn't Impress These Two Wall Street Analysts

19% Upside Predicted For Biogen, Goldman Upgrades On Strength Of Alzheimer's Drug

The Near-Term Setup For Biogen Has Positive Risk/Reward Written All Over It

Analysts Confident In Acceleron Pharma's Drug Trial Outcomes

Acceleron's Luspatercept Is All About Duration, And This Analyst Is Excited About Its Prospects